Stock Traders Purchase Large Volume of Indivior Call Options (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) saw some unusual options trading on Thursday. Investors purchased 4,500 call options on the company. This is an increase of 455% compared to the typical volume of 811 call options.

Indivior Stock Down 0.2%

Shares of INDV opened at $22.81 on Friday. Indivior has a 52-week low of $7.33 and a 52-week high of $25.10. The firm’s fifty day moving average is $22.13 and its two-hundred day moving average is $15.37.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.25. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. The firm had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. Indivior has set its FY 2025 guidance at EPS. As a group, analysts forecast that Indivior will post 1.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on INDV. Wall Street Zen raised shares of Indivior from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 21st. Jefferies Financial Group initiated coverage on shares of Indivior in a research report on Tuesday, July 22nd. They set a “buy” rating and a $20.00 price target on the stock. HC Wainwright initiated coverage on shares of Indivior in a research report on Wednesday, August 6th. They issued a “buy” rating and a $27.00 price objective for the company. Finally, Craig Hallum increased their target price on shares of Indivior from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to data from MarketBeat.com, Indivior currently has an average rating of “Buy” and an average target price of $22.00.

Institutional Investors Weigh In On Indivior

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Indivior during the second quarter worth $26,000. GF Fund Management CO. LTD. purchased a new position in shares of Indivior during the 4th quarter worth $36,000. Amalgamated Bank acquired a new position in shares of Indivior during the 2nd quarter valued at about $61,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new stake in Indivior during the first quarter worth about $95,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.